Cargando…

Beliefs about chelation among thalassemia patients

BACKGROUND: Understanding patients’ views about medication is crucial to maximize adherence. Thalassemia is a congenital blood disorder requiring chronic blood transfusions and daily iron chelation therapy. METHODS: The Beliefs in Medicine Questionnaire (BMQ) was used to assess beliefs in chelation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trachtenberg, Felicia L, Mednick, Lauren, Kwiatkowski, Janet L, Neufeld, Ellis J, Haines, Dru, Pakbaz, Zahra, Thompson, Alexis A, Quinn, Charles T, Grady, Robert, Sobota, Amy, Olivieri, Nancy, Horne, Robert, Yamashita, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545841/ https://www.ncbi.nlm.nih.gov/pubmed/23216870 http://dx.doi.org/10.1186/1477-7525-10-148

Ejemplares similares

Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone
por: Porter, John B, et al.
Publicado: (2013)

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem
por: Vogiatzi, Maria G, et al.
Publicado: (2009)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
por: Eziefula, Chinea, et al.
Publicado: (2022)

Successful chelation in beta-thalassemia major in the 21(st) century
por: Fragodimitri, Christina, et al.
Publicado: (2023)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

Cardiac Function and Iron Chelation in Thalassemia Major and Intermedia: a Review of the Underlying Pathophysiology and Approach to Chelation Management
por: Aessopos, Athanasios, et al.
Publicado: (2009)

Prospective changes of cardiac iron and function by MR in pediatric thalassemia major patients treated with different chelators or not chelated
por: Meloni, Antonella, et al.
Publicado: (2015)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Knowledge and Beliefs Regarding Thalassemia in an Urban Population
por: Ebrahim, Sidra, et al.
Publicado: (2019)

Spinal cord compression due to extramedullary hematopoiesis in a patient with E-beta-thalassemia managed without radiation or surgery
por: La, Van T., et al.
Publicado: (2018)

Hb E/beta-thalassaemia: a common & clinically diverse disorder
por: Olivieri, Nancy F., et al.
Publicado: (2011)

Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: Our experience
por: Jethani, Jitendra, et al.
Publicado: (2010)

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
por: Punzo, Francesca, et al.
Publicado: (2018)

Economic Evaluation of Chelation Regimens for β-Thalassemia Major: a Systematic Review
por: Li, Jialian, et al.
Publicado: (2019)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
por: Meloni, Antonella, et al.
Publicado: (2022)

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
por: Pennell, DJ, et al.
Publicado: (2011)

Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
por: Veríssimo, Monica Pinheiro de Almeida, et al.
Publicado: (2013)

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
por: Saliba, Antoine N, et al.
Publicado: (2015)

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
por: Susanah, Susi, et al.
Publicado: (2020)

A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia
por: Reddy, Paavani S., et al.
Publicado: (2022)

Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia
por: Reisi, Nahid, et al.
Publicado: (2022)

Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients
por: Chawsamtong, Sriwatree, et al.
Publicado: (2022)

Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
por: Nuzzi, Raffaele, et al.
Publicado: (2021)

Management of transfusional iron overload – differential properties and efficacy of iron chelating agents
por: Kwiatkowski, Janet L
Publicado: (2011)

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
por: Tanner, Mark A, et al.
Publicado: (2008)

Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients
por: Khan, Muhammad Ali, et al.
Publicado: (2019)

Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective
por: Li, Jialian, et al.
Publicado: (2020)

Renal function in β-thalassemia major patients treated with two different iron-chelation regimes
por: Tanous, Osama, et al.
Publicado: (2021)

Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study
por: Hamed, Enas A, et al.
Publicado: (2010)

Thalassemia Major in Adults: Short Stature, Hyperpigmentation, Inadequate Chelation, and Transfusion-Transmitted Infections are Key Features
por: Prakash, Anupam, et al.
Publicado: (2012)

Acute cardiac decompensation in a patient with beta‐thalassemia and diabetes mellitus following cessation of chelation therapy
por: Lioudaki, Eirini, et al.
Publicado: (2016)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
por: Zarghamian, Parinaz, et al.
Publicado: (2020)

Chelating Agents and the Regulation of Metal Ions
por: Bulman, Robert A.
Publicado: (1994)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major
por: Ejaz, Muzamil Shabana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3momvajtq2angpaqku90n7ef30